High cancer drug prices in the United States: reasons and proposed solutions.

@article{Kantarjian2014HighCD,
  title={High cancer drug prices in the United States: reasons and proposed solutions.},
  author={Hagop M Kantarjian and David P. Steensma and Judit Rius Sanjuan and Adam G Elshaug and Donald W. Light},
  journal={Journal of oncology practice},
  year={2014},
  volume={10 4},
  pages={
          e208-11
        }
}
The increase in cancer drug prices in the last 15 years has many contributing factors and is harming our patients and our health care system. It represents to many cancer experts a crossing of a moral line between reasonable profits and profiteering, in a situation involving a human catastrophe: patients who have developed cancer, and who may die because they cannot afford the treatment. With typical out-of-pocket expenses of 20% to 30%, the financial burden of cancer treatment would be $20,000… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

Improving access to high-cost cancer drugs in Latin America: Much to be done.

VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

340B Drug Pricing Program: The Expansion and Its Effect on Cancer Care.

  • Clinical journal of oncology nursing
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2018